REG - Oncimmune Hldgs PLC - Appointment of Nominated Adviser and Joint Broker

Oncimmune HoldingsAnnouncement

26/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240426:nRSZ0978Ma&default-theme=true

RNS Number : 0978M  Oncimmune Holdings PLC  26 April 2024

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Appointment of Nominated Adviser and Joint Broker

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company
to the pharmaceutical and biotechnology industry enabling precision medicine,
announces the appointment of Cavendish Capital Markets Limited as Nominated
Adviser and Joint Broker with immediate effect. Zeus Capital Limited will
remain as the Company's Joint Broker.

 

For further information please contact:

 

 Oncimmune Holdings plc
 contact@oncimmune.com

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
 Geoff Nash, George Dollemore, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks, Ondraya Swanson (ECM)

 +44 (0) 20 7220 0500

 Zeus Capital Limited (Joint Broker)
 Dominic King, Victoria Ayton, Dan Bate

 +44 (0)20 3829 5000

 +44 (0)20 3727 1000

 

Notes to Editors

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

 

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

 

Existing Board - AIM Rule 17 Disclosure

 

The Company announces the following additional director disclosures pursuant
to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

Alistair Macdonald - Chairman

 

Alistair Macdonald was a former director of Taiwan Syneos Health Company
Limited and Inc Research SA within 5 years of the date of the Company's
announcement entitled "Board changes and Trading Update" dated 8 July 2022.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPPPUUPCUPCGAA